Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

argenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016

argenx N.V.
Posted on: 19 Aug 16

Breda, the Netherlands / Ghent, Belgium - argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, August 26, 2016 at 3:00pm CET (9:00am EDT) to discuss financial results for the first half of 2016, as well as to provide a second quarter business update.

To participate in the conference call, please select your phone number below and use the confirmation code 49998398. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here

A replay of the webcast will also be available at the argenx website.

About argenx

argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

argenx is listed on the Euronext Brussels exchange under the symbol ARGX.

www.argenx.com

 

Dial-In Numbers:

Participant Free Call Dial-In Numbers:

 

 

UK0800 694 0257

 

 
Participant Standard International Dial-In:

 

UK Standard International+44 (0) 1452 555 566

 

 
Participant UK Local Call Dial-In Numbers:

 

UK0844 493 3800
UK National Call0871 700 0345

 

 
Participant Local Call Dial-In Numbers:

 

Australia0290 371 687
Austria0192 865 68
Belgium0817 000 61
Croatia0177 766 11
Czech Republic2288 804 60
Denmark3272 7625
Finland0923 195 187
France0176 742 428
Germany0692 222 3479
Germany0692 222 4918
Hungary0618 088 303
India0223 098 5304
Ireland0143 196 48
Ireland0150 601 53
Italy0236 008 146
Latvia6778 2516
Luxembourg2088 0695
Netherlands0207 176 886
New Zealand0992 917 07
Norway2156 3013
Poland2230 701 18
Romania0318 144 957
Russia4996 771 036
Slovenia0160 093 64
South Africa2110 032 02
Spain9141 436 69
Sweden0850 336 434
Switzerland0565 800 007
USA1631 510 7498

For further information, please contact:

Joke Comijn, Corporate Communications Manager

+32 (0)477 77 29 44

+32 (0)9 310 34 19

info@argenx.com

 

Beth DelGiacco (US IR)

Stern Investor Relations

+1 212 362 1200

beth@sternir.com

 

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx' actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: argenx N.V. via GlobeNewswire
HUG#2032952
GlobeNewswire
globenewswire.com

Last updated on: 22/08/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.